Sentynl Therapeutics, a U.S. based biopharmaceutical company and a wholly-owned subsidiary of Zydus Lifesciences and BridgeBio Pharma, a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, announced the execution of an asset purchase agreement for the sale of BridgeBio's Nulibry (Fosdenopterin) injection. Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder.

With the asset purchase of Nulibry, Zydus Lifesciences aims at bridging the unmet healthcare needs of children with rare and orphan paediatric diseases. The company's wholly-owned subsidiary Sentynl is also facilitating early diagnosis and treatment by enhancing awareness, new-born screening, genetic testing and patient support across multiple products and rare diseases including the development of a treatment for Menkes Disease, currently under rolling review by the USFDA, for which it partnered with Cyprium Therapeutics.

Under the terms of the agreement, Sentynl will acquire global rights to Nulibry and will be responsible for the ongoing development and commercialisation of Nulibry in the United States and developing, manufacturing and commercialising it globally. BridgeBio will share development responsibilities for Fosdenopterin through approval of the marketing authorisation application already under accelerated assessment with the European Medicines Agency and through approval of its regulatory submission with the Israeli Ministry of Health. Sentynl will provide cash payments upon the achievement of certain regulatory milestones. BridgeBio will be eligible to receive commercial milestone payments as well as tiered royalties on adjusted net sales of NULIBRY.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, said, "We are focused on our core purpose to empower patients suffering from rare disease with the freedom to live healthier and fulfilled lives. Molybdenum cofactor deficiency (MoCD) is an unmet healthcare need affecting newborns. With this, we aim to make a radical contribution to the lives of children suffering from this disease. This agreement further adds to our portfolio of medicines for rare and orphan diseases."